

# Zhijie Wang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9843091/zhijie-wang-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71  
papers

2,182  
citations

24  
h-index

46  
g-index

88  
ext. papers

3,066  
ext. citations

6  
avg, IF

4.77  
L-index

#	Paper	IF	Citations
71	MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.. <i>Molecular Diagnosis and Therapy</i> , <b>2022</b> , 26, 203	4.5	3
70	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. <i>Journal of the National Cancer Center</i> , <b>2021</b> , 1, 153-153		0
69	Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays.. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 4336-4352	4.4	1
68	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based p.T790M in non-small-cell lung cancer patients. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 3888-3901	4.4	3
67	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. <i>BMC Medicine</i> , <b>2021</b> , 19, 239	11.4	0
66	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 709-717	13.4	45
65	Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21002-e21002	2.2	
64	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 8522-8522	2.2	2
63	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	2
62	International consensus on severe lung cancer-the first edition. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 2633-2666	4.4	2
61	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1099-1117	8.9	11
60	Evaluation of radical surgical treatment in the management of 58 locally advanced rectal neuroendocrine neoplasms, one multicenter retrospective study. <i>European Journal of Surgical Oncology</i> , <b>2021</b> ,	3.6	1
59	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 66-78 <sup>3-2</sup>	3.2	10
58	TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211038477	5.4	6
57	Bevacizumab combined with pemetrexed successfully treated lung adenocarcinoma complicated with pulmonary tumor thrombotic microangiopathy: a case report and literature review. <i>Annals of Palliative Medicine</i> , <b>2021</b> , 10, 767-777	1.7	1
56	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1265-1274	21.7	15
55	Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 801741	5.7	0

54	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. <i>Npj Precision Oncology</i> , <b>2020</b> , 4, 32	9.8	8
53	Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1116-1117	13.4	
52	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1149-1159	3.2	2
51	The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. <i>Journal of Cancer</i> , <b>2020</b> , 11, 3106-3115	13.5	2
50	Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. <i>JAMA Oncology</i> , <b>2020</b> , 6, 631-632	13.4	59
49	In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, e72-e73	8.9	
48	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 146-154	12.5	72
47	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 816-826	8.9	106
46	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer. <i>JAMA Oncology</i> , <b>2020</b> , 6, 932	13.4	0
45	Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 713-722	3.2	2
44	Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e13528-e13528	2.2	
43	The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 1209-1219	8.8	23
42	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 556-567	8.9	27
41	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2020</b> , 6, 375-384	13.4	110
40	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2013770	10.4	15
39	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3501-3509	3.2	3
38	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. <i>Nature Communications</i> , <b>2020</b> , 11, 4878	17.4	6
37	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 527750	8.4	3

36	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , <b>2020</b> , 147, 259-268	5.9	9
35	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1857-1870	8.9	7
34	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. <i>BMC Medicine</i> , <b>2020</b> , 18, 232	11.4	7
33	Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 7151-7164	3.6	3
32	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5049-5060	12.9	31
31	Hypoxia-inducible factor-1 $\alpha$ and nuclear factor- $\kappa$ B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. <i>Cancer Science</i> , <b>2019</b> , 110, 1665-1675	6.9	28
30	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer <b>2019</b> , 7, 198		19
29	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , <b>2019</b> , 5, 696-702	13.4	237
28	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. <i>Cancer Letters</i> , <b>2019</b> , 440-441, 180-188	9.9	12
27	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. <i>Cancer Research</i> , <b>2019</b> , 79, 7-20	10.1	63
26	Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic Profiling. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2100-2109	12.9	28
25	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1166-1173	3.2	7
24	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. <i>Lancet Respiratory Medicine</i> , <b>2018</b> , 6, 681-690	35.1	103
23	Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3024-3024	2.2	1
22	Associations between mutations of DNA damage response and prognosis in microsatellite instability prevalent tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e24257-e24257	2.2	
21	The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15007-e15007	2.2	
20	Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21184-e21184	2.2	
19	Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12034-12034	2.2	

18	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1716-1724	3.2	1
17	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. <i>Cancer Research</i> , <b>2018</b> , 78, 6486-6496	10.1	104
16	Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 805-813	3.2	3
15	Analysis of mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. <i>Oncology Letters</i> , <b>2017</b> , 13, 2425-2431	2.6	11
14	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1376-1387	8.9	29
13	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1766-1778	8.9	35
12	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2016</b> , 28, 12-8	3.8	1
11	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , <b>2016</b> , 7, 35132-43	3.3	9
10	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 20810-24	3.3	63
9	High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. <i>Thoracic Cancer</i> , <b>2016</b> , 7, 100-10	3.2	9
8	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 9990-5	11.5	24
7	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. <i>PLoS ONE</i> , <b>2014</b> , 9, e110780	3.7	109
6	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 21083-8	11.5	344
5	Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e54170	3.7	76
4	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3077-83	2.2	154
3	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. <i>Oncology</i> , <b>2012</b> , 83, 248-56	3.6	36
2	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. <i>Thoracic Cancer</i> , <b>2012</b> , 3, 334-340	3.2	35
1	Systematic investigations of COVID-19 in 283 cancer patients		5

